A phase 1 clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA and of MF59-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants,
Enrollment Opened
Objectives
-To evaluate safety and tolerability of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.
-To evaluate immune responses of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.
Trial design
Multicenter, randomized, controlled, double-blind trial conducted in six sites in Southern African countries.
Funder/Sponsor
NIH/DAIDS HVTN
